• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Cullinan Therapeutics Inc.

    1/6/25 4:22:42 PM ET
    $CGEM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CGEM alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001838061
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    CULLINAN THERAPEUTICS, INC.
    SEC File Number
    001-39856
    Address of Issuer
    One Main Street, Suite 1350
    Cambridge
    MASSACHUSETTS
    02142
    Phone
    6174104650
    Name of Person for Whose Account the Securities are To Be Sold
    JENNIFER MICHAELSON
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    COMMON
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    8000101440.005822759301/06/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common12/16/2019Restricted Stock UnitsIssuerCheckbox not checked452312/16/2019N/A
    Common01/06/2025Exercise of Stock OptionsIssuerCheckbox not checked347701/06/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    JENNIFER MICHAELSON
    One Main Street, Suite 1350
    Cambridge � MA � 02142
    Common12/18/2024469353547.13
    JENNIFER MICHAELSON
    One Main Street, Suite 1350
    Cambridge � MA � 02142
    Common12/12/2024348943682.28
    10b5-1 Sales for JENNIFER MICHAELSON
    One Main Street, Suite 1350
    Cambridge � MA � 02142
    COMMON11/05/20248000125102.80

    144: Remarks and Signature

    Remarks
    The securities to be sold were acquired upon the vesting of restricted stock units during the period of 12/16/2023 through 12/17/2023 The securities to be sold will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment will be the dates of exercise/sale.
    Date of Notice
    01/06/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    01/05/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Jennifer Michaelson

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $CGEM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CGEM

    DatePrice TargetRatingAnalyst
    10/24/2024$30.00Buy
    UBS
    5/1/2024$40.00Buy
    Stifel
    4/15/2024Outperform
    William Blair
    2/15/2024$30.00Outperform
    Wedbush
    6/15/2023Outperform
    TD Cowen
    11/21/2022$20.00Buy
    BTIG Research
    More analyst ratings

    $CGEM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Taiho Oncology and Cullinan Therapeutics Announce Pivotal REZILIENT1 Phase 1/2 Data Published in the Journal of Clinical Oncology

      PRINCETON, N.J. and CAMBRIDGE, Mass., June 1, 2025 /PRNewswire/ -- Taiho Oncology, Inc., and Cullinan Therapeutics, Inc., announced today the publication of positive results from the REZILIENT1 trial in the peer-reviewed Journal of Clinical Oncology (JCO). REZILIENT1 is a Phase 1/2, global, multicenter study of zipalertinib (development code: CLN-081/TAS6417) in patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who have received prior therapy. Results from the REZILIENT1 trial will be presented in a simultaneous oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (Abst

      6/1/25 8:21:00 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference

      CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its management team will host a company event at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL and will participate in the Jefferies 2025 Global Healthcare Conference, being held June 3-5, 2025 in New York, NY. The Company will host an in-person event for analysts and institutional investors on Sunday, June 1, 2025, at 6:30 p.m. CT during the 2025 ASCO Annual Meeting in Chicago, IL. The event will follow the oral presentation of results from th

      5/29/25 7:00:00 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

      CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b cohorts of the REZILIENT1 trial, a Phase 1/2 clinical trial of zipalertinib monotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (ex20ins) who have received prior therapy. These data will be presented on Sunday, June 1 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting as an oral presentation during the "Lung Cancer –

      5/22/25 5:15:01 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEM
    Financials

    Live finance-specific insights

    See more
    • Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

      Company received approval from European Medicines Agency (EMA) for CLN-978; Phase 1 study in active, difficult-to-treat rheumatoid arthritis to initiate in Q2 2025 CLN-978 expands into Sjögren's disease; Phase 1 study in active, moderate to severe patients to initiate in the U.S. in Q2 2025 Zipalertinib REZILIENT1 results to be shared in oral presentation at 2025 ASCO Annual Meeting CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the first

      5/8/25 7:00:00 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

      Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) expected in Q4 2025; CLN-978 remains the first and only development-stage CD19 T cell engager in an autoimmune disease clinical trial in the U.S. Zipalertinib pivotal Phase 2b study met primary endpoint; full results mid-year 2025 and NDA submission planned H2 2025, pending regulatory discussions Cash and investments of $606.9 million as of December 31, 2024, continues to provide runway into 2028 CAMBRIDGE, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted t

      2/27/25 7:00:32 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results

      Global Phase 1 study of CLN-978 in systemic lupus erythematosus (SLE) cleared to initiate in U.S. and Australia; initial clinical data expected in Q4 2025 CLN-619 on-track for initial expansion cohort data in endometrial and cervical cancers in Q2 2025 Zipalertinib pivotal Phase 2b study enrollment completed ahead of schedule; results expected mid-year 2025 CAMBRIDGE, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM, "Cullinan")), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today reported recent and anticipated business highlights and announced its financial results for the third quarter ended September 30, 202

      11/7/24 7:00:00 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

      SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

      11/14/24 5:05:22 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

      SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

      11/14/24 4:24:39 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cullinan Therapeutics Inc.

      SC 13G/A - Cullinan Therapeutics, Inc. (0001789972) (Subject)

      11/12/24 2:23:54 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Ahmed Nadim sold $106,872 worth of shares (12,529 units at $8.53), decreasing direct ownership by 3% to 430,621 units (SEC Form 4)

      4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

      2/27/25 5:00:07 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Medical Officer Jones Jeffrey Alan sold $41,754 worth of shares (4,895 units at $8.53), decreasing direct ownership by 3% to 174,164 units (SEC Form 4)

      4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

      2/27/25 5:00:09 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chief Scientific Officer Michaelson Jennifer sold $32,039 worth of shares (3,756 units at $8.53), decreasing direct ownership by 3% to 142,004 units (SEC Form 4)

      4 - Cullinan Therapeutics, Inc. (0001789972) (Issuer)

      2/27/25 5:00:06 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • UBS initiated coverage on Cullinan Therapeutics with a new price target

      UBS initiated coverage of Cullinan Therapeutics with a rating of Buy and set a new price target of $30.00

      10/24/24 6:18:20 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Stifel initiated coverage on Cullinan Management with a new price target

      Stifel initiated coverage of Cullinan Management with a rating of Buy and set a new price target of $40.00

      5/1/24 6:23:49 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • William Blair initiated coverage on Cullinan Management

      William Blair initiated coverage of Cullinan Management with a rating of Outperform

      4/15/24 7:38:02 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEM
    Leadership Updates

    Live Leadership Updates

    See more
    • Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer

      CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced the appointment of Mary Kay Fenton as Chief Financial Officer, beginning April 29. "I am pleased to welcome Mary Kay to Cullinan Therapeutics as Chief Financial Officer. This is a pivotal time for Cullinan as we expand into autoimmune diseases and continue to advance our clinical-stage oncology portfolio," said Nadim Ahmed, Chief Executive Officer, Cullinan Therapeutics. "Mary Kay brings a wealth of expertise to our team with a successful track record marked by pivotal roles leading in a variety of fast

      4/29/24 7:00:00 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cullinan Oncology Announces the Appointment of David P. Ryan, M.D. to its Board of Directors

      CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan Oncology"), a biopharmaceutical company focused on modality-agnostic targeted oncology for patients with cancer, today announced that David P. Ryan, M.D. has been appointed to the company's Board of Directors ("Board"). Dr. Ryan brings over 20 years of oncology experience and joins Cullinan Oncology from Massachusetts General Hospital ("MGH") Cancer Center where he holds the position of Clinical Director and has been the Chief of the MGH Cancer Center since 2012.   Dr. Ryan holds a doctoral degree in medicine from Columbia College of Physicians and Surgeons. Following the completion of his

      11/2/22 8:00:00 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cullinan Oncology Announces Appointment of Jacquelyn Sumer as Chief Legal Officer

      CAMBRIDGE, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (NASDAQ:CGEM) ("Cullinan Oncology"), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapeutic candidates across multiple modalities for patients with cancer, today announced that Jacquelyn (Jackie) Sumer, J.D., will join the company as Chief Legal Officer. Jackie brings with her nearly two decades of legal and strategic leadership experience, with proven skills in navigating legal and compliance issues through clinical development and commercialization of cancer therapies. "The appointment of Jackie as Chief Legal Officer brings her exceptional expertise and legal guidance a

      8/15/22 4:57:42 PM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CGEM
    SEC Filings

    See more
    • SEC Form 10-Q filed by Cullinan Therapeutics Inc.

      10-Q - Cullinan Therapeutics, Inc. (0001789972) (Filer)

      5/8/25 7:24:46 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cullinan Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Cullinan Therapeutics, Inc. (0001789972) (Filer)

      5/8/25 7:21:22 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Cullinan Therapeutics Inc.

      DEFA14A - Cullinan Therapeutics, Inc. (0001789972) (Filer)

      4/25/25 6:58:58 AM ET
      $CGEM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care